Abnormal proteins at inflammation sites

The name "Abnormal proteins at inflammation sites" does not correspond to a specific, canonical therapeutic target but is a general descriptor used to refer to proteins whose levels, structure, or posttranslational modifications are altered in inflammatory microenvironments. These may include acute-phase reactants (e.g., C-reactive protein, haptoglobin), altered cell surface proteins, immunoglobulins, or disease-associated misfolded or aggregated proteins. Identification of such proteins by proteomic analysis has been useful for biomarker discovery and understanding disease mechanisms, such as in autoimmune diseases and neuroinflammation[1][2][4][6]. However, for drug discovery, specific protein names and structures must be used. Therefore, the designation as a "target" is **incorrect and insufficiently specific** for structured data extraction or therapeutic strategy.